Vivian W L Tsang, Dragos C Ragazan, Pamela Kryskow, Zach Walsh, Shannon Dames
{"title":"一项比较有和没有同时进行氯胺酮辅助治疗的实践社区项目的试点研究。","authors":"Vivian W L Tsang, Dragos C Ragazan, Pamela Kryskow, Zach Walsh, Shannon Dames","doi":"10.1080/02791072.2023.2253798","DOIUrl":null,"url":null,"abstract":"<p><p>The prevalence of depression, anxiety, and post-traumatic stress disorder (PTSD) has increased among healthcare providers, while the effectiveness of conventional treatments remains limited. Ketamine-assisted therapy offers a promising alternative; however, few have integrated ketamine with a group-based therapeutic modality. We report a retrospective, secondary analysis of a 12-week pilot of a Community of Practice (CoP) oriented group therapy program with optional, adjunct ketamine for depression, anxiety, and PTSD in a sample of 57 healthcare providers. All participants moved through the treatment as one group, with 38 electing to also receive three adjunct ketamine sessions in addition to the weekly CoP. Symptoms were assessed at baseline and pilot completion with the PHQ-9 for depression, GAD-7 for anxiety, and PCL-5 for PTSD. We observed significant reductions in the mean change among all participants, suggesting that benefit was derived from the CoP component, with or without ketamine as an adjunct. PHQ-9 scores decreased by 6.79 (95% CI: 5.09-8.49, <i>p</i> < .001), GAD-7 scores decreased by 5.57 (CI: 4.12-7.00, <i>p</i> < .001), and PCL-5 scores decreased by 14.83 (CI: 10.27-19.38, <i>p</i> < .001). Reductions were larger, but statistically nonsignificant, among those receiving ketamine. Further research is required to assess the impact of ketamine as an adjunct in group-based therapies.</p>","PeriodicalId":16902,"journal":{"name":"Journal of psychoactive drugs","volume":" ","pages":"627-636"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Pilot Study Comparing a Community of Practice Program with and without Concurrent Ketamine-Assisted Therapy.\",\"authors\":\"Vivian W L Tsang, Dragos C Ragazan, Pamela Kryskow, Zach Walsh, Shannon Dames\",\"doi\":\"10.1080/02791072.2023.2253798\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The prevalence of depression, anxiety, and post-traumatic stress disorder (PTSD) has increased among healthcare providers, while the effectiveness of conventional treatments remains limited. Ketamine-assisted therapy offers a promising alternative; however, few have integrated ketamine with a group-based therapeutic modality. We report a retrospective, secondary analysis of a 12-week pilot of a Community of Practice (CoP) oriented group therapy program with optional, adjunct ketamine for depression, anxiety, and PTSD in a sample of 57 healthcare providers. All participants moved through the treatment as one group, with 38 electing to also receive three adjunct ketamine sessions in addition to the weekly CoP. Symptoms were assessed at baseline and pilot completion with the PHQ-9 for depression, GAD-7 for anxiety, and PCL-5 for PTSD. We observed significant reductions in the mean change among all participants, suggesting that benefit was derived from the CoP component, with or without ketamine as an adjunct. PHQ-9 scores decreased by 6.79 (95% CI: 5.09-8.49, <i>p</i> < .001), GAD-7 scores decreased by 5.57 (CI: 4.12-7.00, <i>p</i> < .001), and PCL-5 scores decreased by 14.83 (CI: 10.27-19.38, <i>p</i> < .001). Reductions were larger, but statistically nonsignificant, among those receiving ketamine. Further research is required to assess the impact of ketamine as an adjunct in group-based therapies.</p>\",\"PeriodicalId\":16902,\"journal\":{\"name\":\"Journal of psychoactive drugs\",\"volume\":\" \",\"pages\":\"627-636\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of psychoactive drugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/02791072.2023.2253798\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PSYCHOLOGY, CLINICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of psychoactive drugs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/02791072.2023.2253798","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
摘要
医疗保健提供者中抑郁症、焦虑症和创伤后应激障碍(PTSD)的患病率有所上升,而传统治疗的有效性仍然有限。氯胺酮辅助治疗提供了一种有前景的替代方案;然而,很少有人将氯胺酮与基于群体的治疗模式相结合。我们报告了一项为期12周的以实践社区(CoP)为导向的团体治疗计划试点的回顾性二次分析,该计划在57名医疗保健提供者的样本中使用可选的辅助氯胺酮治疗抑郁症、焦虑症和创伤后应激障碍。所有参与者作为一组接受治疗,其中38人选择除了每周CoP外,还接受三次氯胺酮辅助治疗。在基线和试点完成时,用PHQ-9对抑郁进行评估,GAD-7对焦虑进行评估,PCL-5对PTSD进行评估。我们观察到所有参与者的平均变化显著减少,这表明无论是否使用氯胺酮作为辅助药物,CoP成分都能带来益处。PHQ-9评分下降6.79(95%可信区间:5.09-8.49,p p p
A Pilot Study Comparing a Community of Practice Program with and without Concurrent Ketamine-Assisted Therapy.
The prevalence of depression, anxiety, and post-traumatic stress disorder (PTSD) has increased among healthcare providers, while the effectiveness of conventional treatments remains limited. Ketamine-assisted therapy offers a promising alternative; however, few have integrated ketamine with a group-based therapeutic modality. We report a retrospective, secondary analysis of a 12-week pilot of a Community of Practice (CoP) oriented group therapy program with optional, adjunct ketamine for depression, anxiety, and PTSD in a sample of 57 healthcare providers. All participants moved through the treatment as one group, with 38 electing to also receive three adjunct ketamine sessions in addition to the weekly CoP. Symptoms were assessed at baseline and pilot completion with the PHQ-9 for depression, GAD-7 for anxiety, and PCL-5 for PTSD. We observed significant reductions in the mean change among all participants, suggesting that benefit was derived from the CoP component, with or without ketamine as an adjunct. PHQ-9 scores decreased by 6.79 (95% CI: 5.09-8.49, p < .001), GAD-7 scores decreased by 5.57 (CI: 4.12-7.00, p < .001), and PCL-5 scores decreased by 14.83 (CI: 10.27-19.38, p < .001). Reductions were larger, but statistically nonsignificant, among those receiving ketamine. Further research is required to assess the impact of ketamine as an adjunct in group-based therapies.